A Single Center Real-world Observational Study of Response to Dacarbazine or Dacarbazine Combinations in Metastatic Melanoma Refractory to Immunotherapy
Anticancer Research · 2026-08 · 46 (8) · 4471-4477
DOI: 10.21873/anticanres.18303 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Anticancer Research, online erschienen am 29.07.2026. Verfasst von Maleeha Anwar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Velindre University NHS Trust, Cardiff, U.K.; maleeha.anwar@wales.nhs.uk. Hauptthemen laut MEDLINE: Dacarbazine, Melanoma, Antineoplastic Combined Chemotherapy Protocols, Skin Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Velindre University NHS Trust, Cardiff, U.K.; maleeha.anwar@wales.nhs.uk.
- Department of Clinical and Social Epidemiology, University of Exeter, Exeter, U.K.
- Department of Medical Oncology, Velindre University NHS Trust, Cardiff, U.K.
Zitieren
APA
Anwar, M., Melendez-Torres, G. J., & Frazer, R. D. (2026). A Single Center Real-world Observational Study of Response to Dacarbazine or Dacarbazine Combinations in Metastatic Melanoma Refractory to Immunotherapy. Anticancer Research, 46(8), 4471-4477. https://doi.org/10.21873/anticanres.18303
Vancouver
Anwar M, Melendez-Torres GJ, Frazer RD. A Single Center Real-world Observational Study of Response to Dacarbazine or Dacarbazine Combinations in Metastatic Melanoma Refractory to Immunotherapy. Anticancer Research. 2026;46(8):4471-4477. doi:10.21873/anticanres.18303
BibTeX
@article{Anwar2026,
author = {Anwar, Maleeha and Melendez-Torres, G J and Frazer, Ricky Dylan},
title = {A Single Center Real-world Observational Study of Response to Dacarbazine or Dacarbazine Combinations in Metastatic Melanoma Refractory to Immunotherapy},
journal = {Anticancer Research},
year = {2026},
volume = {46},
number = {8},
pages = {4471--4477},
doi = {10.21873/anticanres.18303}
}
EUVIMED